In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
about
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavirLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.New approaches in the management of chronic hepatitis B: role of tenofovir.Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.Pathobiology of HBV mutants and clinical impact for treatment monitoring.HBV life cycle and novel drug targets.Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus.2-[(4-Chloro-benz-yl)sulfan-yl]-4-(2-methyl-prop-yl)-6-(phenyl-sulfan-yl)pyrimidine-5-carbonitrile.2-[(4-Chloro-benz-yl)sulfanyl]-4-(2-methyl-prop-yl)-6-[3-(trifluoro-meth-yl)anilino]-pyrimidine-5-carbonitrile6-(2-Methyl-prop-yl)-4-oxo-2-sulfanyl-idene-1,2,3,4-tetra-hydro-pyrimidine-5-carbonitrile.No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.Resistance mutations of hepatitis B virus in entecavir-refractory patients.Anti-DNA Virus AgentsEmerging antiviral drugs
P2860
Q28748931-01FC9E17-5CB5-4BFF-887B-57E1701F4ADEQ33417353-FB046692-37E1-4CDB-B04D-4DCBDFA06701Q35026531-B15875CF-DCBE-4C77-91BE-C6B39094B683Q36757579-10DB5A62-FC1D-476E-A82E-0A00E82E3D05Q37432098-2BFE4DA6-9C6B-48BA-9250-EEF132EA1915Q37864117-99C38FF4-E036-4BC5-B627-AA5B78E10F34Q39859839-DC3D6099-D142-4C30-AF55-F5B507DDA9A0Q39876916-C2DED164-5E93-464C-8E31-C57B1DFABAE3Q41730783-D4FC3A8C-B5AC-4C35-ABA6-AA2CCB922FD1Q42153085-0CE3509A-4D5D-4EB5-9820-0E1D54F4559CQ42231313-01A1D090-AA74-43F1-84F5-9B7E9F0B38FCQ42231318-5E12EE45-95CD-433F-B6D6-D9DBB35CE9DFQ42595757-49A63573-B536-485B-B8A5-14CCB2D31B80Q42693130-A1B7A9E1-E606-49AB-88D4-897F93B6073EQ45368315-A1F4DD12-C58B-4618-92FE-2B3391E3F50EQ47098116-72CE5EC2-1B3D-4FEE-ADD0-1CF793A4851BQ52699085-18F6B7F3-1418-4293-BD3E-8BB258417C83Q56786267-7CE51C27-1560-40D1-B873-D8EF2D2C0799Q56786308-64342FCB-E1B5-4464-9F89-4EE3E9572B10
P2860
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vitro activity of 2,4-diami ...... ant hepatitis B virus mutants.
@en
type
label
In vitro activity of 2,4-diami ...... ant hepatitis B virus mutants.
@en
prefLabel
In vitro activity of 2,4-diami ...... ant hepatitis B virus mutants.
@en
P2093
P2860
P356
P1476
In vitro activity of 2,4-diami ...... ant hepatitis B virus mutants.
@en
P2093
Brunelle MN
Lucifora J
P2860
P304
P356
10.1128/AAC.01440-06
P407
P577
2007-03-19T00:00:00Z